Treatment of Acute Ischemic Stroke (ReMEDy II Trial)
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2/3 study to evaluate the safety, tolerability, and efficacy of DM199 in
treating acute ischemic stroke patients presenting with AIS and for whom tPA and a
catheter-based procedure, MT, are not medically appropriate or available due to constraints
of clot location, comorbidity risks, and/or time from onset of stroke (LVO is excluded from
this study). The double-blinded study will be randomized, placebo controlled at up to 75
centers.